Accendra Health received NYSE non-compliance notice

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On October 27, 2026, Accendra Health, Inc. (the "Company") received notice (the "Notice") from the New York Stock Exchange (the "NYSE") that it was not in compliance with the continued listing standard set forth in Section 802.01B of the NYSE's Listed Company Manual ("Section 802.01B") that the Company have an average market capitalization of not less than $50.0 million over a consecutive 30 trading-day period and stockholders' equity of not less than $50.0 million. The Notice has no immediate impact on the listing of the Common Stock on the NYSE¹, subject to the Company's compliance with the NYSE's other continued listing requirements.

The Company intends to consider a number of available alternatives to cure its non-compliance with the applicable criteria in the NYSE's continued listing standards. Pursuant to the Notice the Company has a period of 45 calendar days following receipt of the Notice to submit a business plan that demonstrates how the Company intends to regain compliance with Section 802.01B within 18 months of receipt of the Notice¹. The NYSE will review the business plan and, if accepted, the Company will be subject to quarterly monitoring by the NYSE of the progress of the business plan².

The Company intends to notify the NYSE, within 10 business days of receipt of the Notice, of its intent to submit a business plan to regain compliance with the requirements of Section 802.01B and as set forth in the Notice.

The Notice does not affect the Company's business operations or its reporting obligations with the Securities and Exchange Commission³.

Item 7.01. Regulation FD Disclosure.

On October 30, 2026, the Company issued a press release related to the foregoing. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in Exhibit 99.1 is being furnished pursuant to Item 7.01 of Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

The following materials are filed as exhibits to this Current Report on Form 8-K.

Exhibit Number

Description

99.1

Press Release of the Company, dated October 30, 2026 (furnished pursuant to Item 7.01).

104

Cover Page Interactive Data File ( the cover page XBRL tags are embedded in the Inline XBRL document ).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ACCENDRA HEALTH, INC.

October 30, 2026

/s/ Jonathan A. Leon

Jonathan A. Leon

Executive Vice President and Chief Financial Officer

Accendra Health Receives Continued Listing Standard Notice from NYSE Regarding Market Capitalization and Stockholders' Equity;

Intends to Submit Business Plan and Return to Compliance with NYSE Listing Standard

RICHMOND, VA – October 30, 2026 – Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that on October 27, 2026, it received a notice (the "Notice") from the New York Stock Exchange (the "NYSE") notifying the Company that it is not in compliance with Section 802.01B of the NYSE's continued listing standards that the Company have an average market capitalization of not less than $50.0 million over a consecutive 30 trading-day period and stockholders' equity of not less than $50.0 million. The Notice does not result in the immediate delisting of the Company's Class A Common Stock (the "Common Stock") from the NYSE.

The Company intends to respond to the NYSE within ten business days of receipt of the Notice affirming its intent to submit a business plan. Pursuant to Section 802.01B, the Company has a period of 45 calendar days following receipt of the Notice to submit a business plan that demonstrates how the Company intends to regain compliance with Section 802.01B within 18 months of receipt of the Notice. The NYSE will